FGFR1 and non-small cell lung carcinoma: Our results showed that the selective FGFR1 inhibitor PD173074 could significantly decrease the protein level of pFGFR1 at the concentrations of 0.5 μg mL−1, suggesting the effective inhibition of the FGFR1 pathway in AZD9291 resistant NSCLC cells (Figure 3A).